| Literature DB >> 27826233 |
Timothy West1, Simon Farmer2, Luc Berthouze3, Ashwani Jha4, Martijn Beudel5, Thomas Foltynie4, Patricia Limousin4, Ludvic Zrinzo4, Peter Brown6, Vladimir Litvak7.
Abstract
In this paper we investigated the dopaminergic modulation of neuronal interactions occurring in the subthalamic nucleus (STN) during Parkinson's disease (PD). We utilized linear measures of local and long range synchrony such as power and coherence, as well as Detrended Fluctuation Analysis for Phase Synchrony (DFA-PS)- a recently developed non-linear method that computes the extent of long tailed autocorrelations present in the phase interactions between two coupled signals. Through analysis of local field potentials (LFPs) taken from the STN we seek to determine changes in the neurodynamics that may underpin the pathophysiology of PD in a group of 12 patients who had undergone surgery for deep brain stimulation. We demonstrate up modulation of alpha-theta (5-12 Hz) band power in response to L-DOPA treatment, whilst low beta band power (15-20 Hz) band-power is suppressed. We also find evidence for significant local connectivity within the region surrounding STN although there was evidence for its modulation via administration of L-DOPA. Further to this we present evidence for a positive correlation between the phase ordering of bilateral STN interactions and the severity of bradykinetic and rigidity symptoms in PD. Although, the ability of non-linear measures to predict clinical state did not exceed standard measures such as beta power, these measures may help identify the connections which play a role in pathological dynamics.Entities:
Keywords: Parkinson's disease; coherence; connectivity; criticality; deep brain stimulation (DBS); detrended fluctuation analysis; synchronization
Year: 2016 PMID: 27826233 PMCID: PMC5078477 DOI: 10.3389/fnhum.2016.00517
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Details of DBS patient cohort.
| 1 | 58 | M | 13 | Gait freezing, dyskinesias, pain | 25/43 | Co-careldopa 1000 mg |
| Co-careldopa modified release 125 mg | ||||||
| Amantadine 400 mg | ||||||
| Co-beneldopa 125 mg | ||||||
| Entacapone 600 mg | ||||||
| Rasagiline 1 mg | ||||||
| 2 | 57 | M | 17 | Gait impariment, pain, dyskinesias | 14/54 | Co-careldopa 1125 mg |
| Co-careldopa modified release 250 mg | ||||||
| Co-beneldopa 200 mg | ||||||
| Entacapone 1600 mg | ||||||
| Selegiline 10 mg | ||||||
| Amantadine 200 mg | ||||||
| 3 | 60 | M | 15 | Dyskinesias, gait freezing, bradykinesia, tremor | 10/56 | Co-careldopa 1125 mg |
| Co-beneldopa 250 mg | ||||||
| Ropinirole 18 mg | ||||||
| Selegiline 10 mg | ||||||
| Amantadine 200 mg | ||||||
| 4 | 48 | M | 11 | Gait freezing, tremor | 16/72 | Rasagiline 1 mg |
| Co-careldopa 1250 mg | ||||||
| Entacapone 500 mg | ||||||
| 5 | 52 | M | 12 | Dystonia, motor fluctuations, tremor | 10/35 | Rotigotine 4 mg |
| Stalevo 950 mg | ||||||
| Rasagiline 1 mg | ||||||
| 6 | 58 | F | 10 | Dystonia, dyskinesias, tremor | 16/55 | Pramipexole 3 mg |
| Stalevo 400 mg | ||||||
| Rasagiline 2 mg | ||||||
| Co-beneleldopa 62.5 mg as required | ||||||
| 7 | 55 | M | 15 | Tremor, freezing | 5/19 | Co-beneldopa 1000 mg |
| Ropinirole16 mg | ||||||
| Selegiline10 mg | ||||||
| Amantadine100 mg | ||||||
| 8 | 54 | M | 8 | Gait impariment, dyskinesias, tremor | 18/51 | Cabergoline 4 mg |
| Entacapone 800 mg | ||||||
| Co-careldopa 1200 mg | ||||||
| Amantadine 300 mg | ||||||
| 9 | 58 | F | 14 | Gait freezing, pain, dyskinesias, tremor | 16/55 | Pramipexole 4 mg |
| Stalevo 250 mg | ||||||
| 10 | 53 | M | 17 | Motor fluctuations, dyskinesias, freezing | 9/35 | Sinemet 750 mg |
| Pramipexole 0.54 mg | ||||||
| 11 | 60 | F | 20 | Tremor, dyskinesias, gait impairment | 4/35 | Sinemet CR 200 mg |
| Sinemet 563 mg | ||||||
| Stalevo 300 mg | ||||||
| Rasagiline 1 mg | ||||||
| 12 | 53 | M | 12 | Tremor, freezing, motor fluctuations, gait impairments | 19/53 | Stalevo 750 mg |
| Amantidine 100 mg | ||||||
| Pramipexole 2.64 mg |
All patients have PD and have been treated with deep brain stimulation (DBS) targeted to the STN. The patients' age, gender, duration of PD since diagnosis, predominant clinical features, unified Parkinson's disease rating scale (UPDRS, 2008 part III- Motor Impairment) ON and OFF medication are shown. The score is out of a maximum of 104 with higher scores indicative of increased severity.
Figure 1(A) Schematic of DBS electrode contact placement respective the STN and bipolar derivation of channels. Each electrode comprises 4 contacts montaged to 3 bipolar channels Left/Right 01,12,23 STNr. Contact 0 is targeted to be 2 mm caudal of the center of the STN. (B) Derivation of channel pairs subjected to neurophysiological connectivity analyses. Channel pairings were divided into those within the hemisphere (intra-nuclear, in orange) or between left and right nuclei (inter-nuclear, in green). The intra-nuclear pairs were separated into two separate groups corresponding to those originating from left (L) and right (R) nuclei. Not all contacts are contained within the STN and thus signals are referred to as originating from within the local region of the nuclei which we abbreviate STNr.
Figure 2Example procedure for LFP pre-processing. Example signals are taken from the bipolar STNr R01 channel for a single subject. (A) Raw LFP contains artifacts such a high amplitude fluctuations (amplifier jumps), very low frequency baseline drifts, non-zero DC, and boundary artifacts at the extremities of the time series. (B) The pre-processed signal has been truncated, high pass filtered and large transients removed with missing data replaced via interpolation. The resulting spectra are in (C), (D–F- Same as above but for the ON drug experiment). This data is used as it is for DFA-PS and cross correlation analyses. Spectral analyses are computed on epoched data in which bad trials are removed via Z-score thresholding.
Figure 3Analysis of power spectra and statistics for LFP recordings from STNr when either ON or OFF L-DOPA. (A) Group level power spectra for all 12 subjects and for all channels. The dashed line indicates the 95% analytic confidence limit. There is a clear L-DOPA associated modulation in the alpha-theta band (5–12 Hz) and low beta band (13–20 Hz). There is also significant power in the high beta band (21–30 Hz) although L-DOPA modulation is less prominent. (B) Comparison of band power ON and OFF L-DOPA indicated an increase in alpha-theta power in the ON state whilst low beta was shifted in the OFF. There were no significant changes in mean power detected for high beta. The effect of OFF drug modulation in the low beta band was statistically significant as it was below the Bonferonni corrected P-value. Significance stars indicate range of P-values for a repeated measures ANOVA (*P < 0.05).
Table of results for group level spectral analysis of STN data and comparison of ON/OFF drug effects.
| Alpha-theta | 7.236 | 1.554 | 8.222 | 2.328 | −0.986 | 23 | 0.242 |
| Low beta | 16.028 | 2.302 | 16.319 | 2.308 | −0.292 | 23 | 0.852 |
| High beta | 25.840 | 2.557 | 24.819 | 2.660 | 1.021 | 23 | 0.090 |
| Alpha-theta | 0.702 | 0.236 | 0.595 | 0.283 | 0.106 | 23 | |
| Low beta | 0.327 | 0.125 | 0.494 | 0.284 | −0.167 | 23 | |
| High beta | 0.441 | 0.144 | 0.433 | 0.172 | 0.009 | 23 | 0.822 |
Mean and standard deviations of band power and peak frequency in the Alpha-theta, low beta, and high beta ranges are shown as averages across all channels. P-values are reported for repeated measures ANOVA in which the significance of the differences in mean values ON and OFF drugs are tested (P < 0.05),
indicates cases where non-parametric statistics were used due to non-normality in the sample. Results in bold indicate P-values that remain below the Bonferroni corrected decision level termed α* (see section “Reporting of Statistics” in supplemental material). The number of tests considered is equal to total number conducted for each method [i.e., Frequency − 3 tests (1 ANOVA × 3 Bands)].
Figure 4Correlations of band power with UPDRS for bradykinesia/rigidity scores. (A–C) Scatter plots of band power for alpha-theta, low beta, and high beta bands with OFF state UPDRS. Correlations were first determined to be significant using Spearman's test and in the case of significance a linear regression was plot. The corresponding R is reported alongside as well as the P-value for the test. Low alpha-theta power was associated with less severe motor symptoms whilst for low beta the opposite was true. No relationship was found for high beta band. (D) Correlation of ON-OFF low beta band power with ON-OFF UPDRS. The positive correlation was found to be significant and the subsequent linear regression is shown. The relationship suggests that larger reductions in low beta power when ON drug are associated with a greater therapeutic reduction in motor symptoms when ON compared to OFF.
Figure 5Analysis of STNr functional connectivity within nuclei (intra-nuclear) and between left and right nuclei (inter-nuclear) using coherence (top row) or weighted phase lag index (bottom row). All results are presented as pooled data across all 12 subjects ON and OFF L-DOPA. Dashed line on spectra represent the analytic 0.95% confidence limit. Significance stars for boxplots indicate range of P-values for a repeated measures ANOVA (**P < 0.01). (A) Pooled intra-nuclear coherence spectra. Plots show strong coherence (>0.3) across the three bands of interest. (B) Inter-nuclear coherence spectra. Although weaker in comparison to the intra-nuclear coherence, bilateral STNr coherence remains above significance level for the full frequency bands analyzed. Most however is focused in the alpha-theta band. (C) Boxplot comparison of AUC coherence when ON and OFF L-DOPA. There is evidence for an increase in low and high beta coherence when OFF drug. No significant modulations were found for the inter-nuclear comparisons. (D) Pooled intra-nuclear WPLI spectra. There still remains significant coherence within STNr when removing the zero-lag component. (E) WPLI inter-nuclear spectra. All frequencies show attenuation in comparison to (B) although there is still significant alpha-theta band connectivity. (F) Boxplot comparison of AUC WPLI when ON and OFF L-DOPA. The up-modulation of low beta band connectivity within nuclei in response to L-DOPA when correcting for potential volume conduction effects did not meet the Bonferroni corrected significance threshold.
Table of results for group level coherence analysis and comparison of ON/OFF drug effects.
| Intra | 2.376 | 0.922 | 2.635 | 0.777 | −0.259 | 23 | 0.214 |
| Inter | 1.006 | 0.240 | 1.047 | 0.228 | −0.040 | 10 | 0.600 |
| Intra | 2.165 | 0.952 | 2.927 | 1.335 | −0.762 | 21 | |
| Inter | 0.656 | 0.187 | 0.712 | 0.222 | −0.056 | 10 | 0.330 |
| Intra | 3.079 | 1.205 | 3.495 | 1.289 | −0.416 | 22 | |
| Inter | 0.846 | 0.242 | 0.784 | 0.221 | 0.061 | 11 | 0.403 |
| Intra | 1.670 | 1.199 | 2.219 | 1.375 | −0.548 | 23 | 0.083 |
| Inter | 0.661 | 0.440 | 0.736 | 0.440 | −0.074 | 12 | 0.520 |
| Intra | 1.935 | 1.593 | 3.151 | 1.924 | −1.215 | 23 | |
| Inter | 0.280 | 0.146 | 0.340 | 0.154 | −0.061 | 10 | 0.230 |
| Intra | 1.746 | 1.528 | 3.137 | 2.089 | −1.390 | 21 | |
| Inter | 0.480 | 0.303 | 0.523 | 0.379 | −0.043 | 12 | 0.724 |
Mean and standard deviations of the integrated coherence and WPLI coherence in the Alpha-theta, low beta, and high beta ranges are shown for intra-/inter- nuclear and all pairs of contacts. Outlier have been removed. Results from repeated measures ANOVA to examine the significance of drug related modulation in the mean value of coherence are shown in the final column (P < 0.05),
indicates cases where non-parametric statistics were used due to non-normality in the sample. Results in bold indicate P-values that remain below the Bonferroni corrected decision level termed α* (see section “Reporting of Statistics” in supplemental material). The number of tests considered is equal to total number conducted for each method [i.e., Coherence − 6 tests (1 ANOVA × 3 Bands × 2 Pairings)].
Bivariate correlations of UPDRS with power, coherence, and WPLI.
| Intra | −0.609 | 0.331 | 22 | −0.193 | 0.076 | 0.388 | 20 | |
| Inter | −0.616 | 0.386 | 10 | −0.248 | 0.100 | 0.492 | 8 | |
| Intra | 0.662 | 0.390 | 19 | 0.560 | 0.398 | 20 | ||
| Inter | 0.688 | 0.240 | 9 | 0.500 | 0.238 | 0.121 | 9 | |
| Intra | 0.365 | 0.133 | 0.080 | 22 | 0.267 | 0.053 | 0.242 | 19 |
| Inter | 0.518 | 0.229 | 0.084 | 10 | 0.200 | 0.003 | 0.558 | 9 |
| Intra | 0.419 | 0.099 | 22 | 0.368 | 0.100 | 0.076 | 22 | |
| Inter | 0.210 | 0.071 | 0.536 | 9 | −0.510 | 0.431 | 0.094 | 10 |
| Intra | 0.643 | 0.409 | 22 | 0.396 | 0.092 | 0.062 | 21 | |
| Inter | 0.415 | 0.232 | 0.205 | 9 | 0.133 | 0.061 | 0.683 | 10 |
| Intra | 0.459 | 0.211 | 22 | 0.385 | 0.108 | 0.063 | 22 | |
| Inter | 0.551 | 0.094 | 0.079 | 9 | −0.503 | 0.343 | 0.099 | 10 |
| Intra | 0.402 | 0.084 | 0.051 | 22 | 0.433 | 0.017 | 22 | |
| Inter | 0.375 | 0.374 | 0.230 | 10 | 0.392 | 0.197 | 0.210 | 10 |
| Intra | 0.575 | 0.306 | 22 | 0.272 | 0.105 | 0.198 | 22 | |
| Inter | 0.342 | 0.134 | 0.304 | 9 | 0.133 | 0.078 | 0.744 | 7 |
| Intra | 0.074 | 0.007 | 0.732 | 22 | −0.039 | 0.014 | 0.858 | 22 |
| Inter | 0.109 | 0.001 | 0.737 | 10 | −0.636 | 0.346 | 10 | |
Results are shown for OFF L-DOPA UPDRS and the DIFFERENCE (ON-OFF) in UPDRS (bradykinesia/rigidity). Correlations for each metric are computed for each band and for intra- and inter-nuclear sets. In the case of power, the inter-nuclear statistic is the average value between left and right nuclei. The Pearson correlation coefficient (r) is shown alongside the coefficient of determination (R2) for the corresponding linear regression. The P-value and the degrees of freedom for the Spearman's correlations are shown (P > 0.05; ). Results in bold indicate P values that remain below the Bonferroni corrected decision level termed α* (see section “Reporting of Statistics” in supplemental material). The number of tests considered is equal to total number conducted for each method [i.e., Power OFF UPDRS Correlation. − 6 tests (1 t-statistic × 3 Bands × 2 Pairings)].
Table of comparisons of PS-DFA Exponent values for ON or OFF levodopa.
| Intra | 0.548 | 0.021 | 0.548 | 0.044 | 0.000 | 0.980 | 0.031 | 0.073 | −0.042 | ||
| Inter | 0.548 | 0.035 | 0.536 | 0.048 | 0.012 | 0.325 | 0.094 | 0.135 | −0.042 | ||
| Intra | 0.577 | 0.031 | 0.575 | 0.033 | 0.001 | 0.929 | 0.458 | 0.302 | 0.156 | ||
| Inter | 0.549 | 0.023 | 0.554 | 0.029 | −0.005 | 0.536 | 0.365 | 0.333 | 0.031 | ||
| Intra | 0.570 | 0.014 | 0.566 | 0.016 | 0.003 | 0.626 | 0.490 | 0.490 | 0.000 | ||
| Inter | 0.558 | 0.022 | 0.557 | 0.021 | 0.001 | 0.901 | 0.417 | 0.406 | 0.010 | ||
Table shows the mean and standard deviation for exponent values for both ON and OFF L-DOPA treatment. Results for permutation testing of exponents against a set of exponents computed for phase shuffled data are also shown (see section Permutation Statistics). Significance for difference in means between ON and OFF conditions was tested using repeated measures ANOVA (). Exponents are validated using the PEB technique described in section Assessing Fluctuation Plot Linearity. The rejection rate is shown in the three right-most columns. Rejection rates are reported as the percentage of exponents removed from the total set that was computed. Results in bold indicate P values that remain below the Bonferroni corrected decision level termed α* (see section “Reporting of Statistics” in supplemental material). The number of tests considered is equal to total number conducted for each method [i.e., DFA-PS Permutation Stats. − 12 tests (1 Permutation Statistic × 3 Bands × 2 Pairings × 2 Conditions)].
Figure 6Results for analysis with PS-DFA measure for phase ordering between intra-nuclear and inter-nuclear signal pairs. (A–C) Boxplots for PS-DFA exponent values. Comparisons are made between exponents computed from the recorded signals and from a series of 1000 permutated signals. Significant differences were computed using the permutation statistics described in the text P-values (**P < 0.01). No significant changes in exponents were found with application of L-DOPA although all were significant different from signals without any phase ordering. (D) Low beta band bilateral PS-DFA exponents are positively correlated with worse motor symptoms. (E) ON-OFF difference correlations. The correlations suggest that patients with a larger decrease in exponent ON drug also show the best therapeutic effect.
Bivariate correlations of UPDRS with PS-DFA Exponets.
| Intra | 0.054 | 0.014 | 0.807 | 21 | 0.081 | 0.013 | 0.713 | 21 |
| Inter | 0.025 | 0.007 | 0.940 | 10 | 0.517 | 0.305 | 0.089 | 10 |
| Intra | 0.043 | 0.040 | 0.854 | 19 | −0.197 | 0.097 | 0.450 | 15 |
| Inter | 0.725 | 0.471 | 10 | 0.827 | 0.328 | 9 | ||
| Intra | −0.204 | 0.041 | 0.402 | 17 | −0.279 | 0.052 | 0.295 | 14 |
| Inter | −0.074 | 0.013 | 0.820 | 10 | 0.355 | 0.109 | 0.286 | 9 |
Results are shown for OFF L-DOPA UPDRS and the DIFFERENCE (ON-OFF) in UPDRS (bradykinesia/rigidity). Exponents are validated using the PEB method described in Section 2.3.3. The Spearman correlation coefficient (r) is shown alongside the coefficient of determination (R2) for the corresponding regression. The P-value and the degrees of freedom for the correlations are shown (). Results in bold indicate P-values that remain below the Bonferroni corrected decision level termed α* (see section “Reporting of Statistics” in supplemental material). The number of tests considered is equal to total number conducted for each method [i.e., DFA OFF UPDRS Correlation. − 6 tests (1 t-statistic × 3 Bands × 2 Pairings)].
GLM Regression Analysis.
| Alpha-theta power | 0.331 | 0.493 | 0.358 | 0.333 | ||||
| Low beta power | 0.343 | 0.119 | 0.358 | 0.368 | ||||
| High beta power | 0.067 | 0.133 | ||||||
| Alpha-theta power | 0.386 | 0.197 | 0.326 | 0.101 | 0.389 | |||
| Low beta power | 0.089 | 0.210 | ||||||
| High beta power | 0.084 | 0.229 | ||||||
| Alpha-theta coherence | 0.118 | 0.098 | ||||||
| Low beta coherence | 0.409 | 0.450 | 0.059 | 0.448 | 0.418 | |||
| High beta coherence | 0.211 | 0.585 | 0.339 | 0.407 | 0.364 | 0.073 | 0.244 | |
| Alpha-theta coherence | 0.378 | 0.039 | ||||||
| Low beta coherence | 0.095 | 0.205 | ||||||
| High beta coherence | 0.309 | 0.061 | ||||||
| Alpha-theta exponent | 0.574 | 0.023 | ||||||
| Low beta exponent | 0.359 | 0.181 | ||||||
| High beta exponent | 0.380 | 0.028 | ||||||
| Alpha-theta exponent | 0.776 | 0.007 | ||||||
| Low beta exponent | 0.471 | 0.100 | 0.514 | 0.472 | 0.529 | |||
| High beta exponent | 0.700 | 0.013 | ||||||
Results from statistical modeling of UPDRS regression with spectral features such as power in band, coherence, and PS-DFA exponents. The bivariate regressions are shown in the first column with the respective P-value of the predictor for UPDRS and the overall Ω2(estimated explained variance) for the given model. Models with the addition of an extra covariate are given in columns to the right, with the rows signal feature combined into a model alongside either Alpha-theta, low beta or high beta power. For intra-nuclear analyses where there were two samples per subject the model involved a mixed design with random intercepts for each subject (GLMM). The P-value (P < 0.05; ) for the significance of the predictor (row) in the presence of the covariate (column) is given alongside the approximate explained variance. Models in which both covariates are known to be significant independently but both lose significance when entered in a model are marked in red. In these cases, inference of predictor significance cannot be drawn due to collinearity between covariates. Results in bold indicate P-values that remain below the Bonferroni corrected decision level termed α* (see section “Reporting of Statistics” in supplemental material). The number of tests considered is equal to total number conducted for each method [i.e., Power GLMM − 12 tests (1 f-test × 3 Bands × 2 Pairings + 6 multiple regressors models)].
Summary of results from analysis with measures of synchronization in the STN.
| Intra-nuclear | Negative | ↓ | Positive | Positive | |||||
| Intra-nuclear | ↓ | Positive | |||||||
| Inter-nuclear | |||||||||
| Intra-nuclear | Positive | ||||||||
| Inter-nuclear | |||||||||
| Intra-nuclear | |||||||||
| Inter-nuclear | Positive | Positive | |||||||
Statistics are summarized for either the ON/OFF comparison of means with repeated measures ANOVA, OFF UPDRS correlation, or ON-OFF difference correlation for the three bands of interest. Only results with P-values that met the Bonferroni corrected decision level were included (see section “Reporting of Statistics” in supplemental material). Arrows for ON L-DOPA columns indicate the change of given measure from the ON to the OFF state. For OFF/ON-OFF UPDRS, Negative or Positive are displayed in order to show direction of correlation with the given measure.